Article
The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease.
Journal of hypertension - 1 Oct 2005
Testa Alessandra, Spoto Belinda, Tripepi Giovanni, Mallamaci Francesca, Malatino Lorenzo, Fatuzzo Pasquale, Maas Renke, Boeger Rainer, Zoccali Carmine
Abstract excerpt
OBJECTIVES: Impaired nitric oxide generation and accumulation of the endogenous inhibitor of nitric oxide synthase (NOS), asymmetric dimethylarginine (ADMA), have been identified as strong predictors of cardiovascular outcomes in patients with end-stage renal disease (ESRD). We evaluated the role of endothelial NOS (eNOS) gene polymorphisms and its interaction with plasma ADMA in the high cardiovascular...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.